Belzutifan Clinical Trials
11 recruitingDrug
Phase 26Phase 13Phase 33
Showing 1–11 of 11 trials
Recruiting
Phase 2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Metastatic Breast Cancer
Merck Sharp & Dohme LLC120 enrolled41 locationsNCT06428396
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled103 locationsNCT07227402
Recruiting
Phase 3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC758 enrolled3 locationsNCT07489495
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled9 locationsNCT07405164
Recruiting
Phase 1Phase 2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC140 enrolled27 locationsNCT07049926
Recruiting
Phase 1
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Renal Cell Carcinoma
HiberCell, Inc.80 enrolled20 locationsNCT06234605
Recruiting
Phase 2
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07187778
Recruiting
Phase 2
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Ovarian CancerCervical CancerEndometrial Cancer+5 more
Dana-Farber Cancer Institute32 enrolled2 locationsNCT06677190
Recruiting
Phase 1
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
Metastatic Clear Cell Renal Cell Carcinoma
NYU Langone Health12 enrolled1 locationNCT07179770
Recruiting
Phase 2
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Von Hippel Lindau
José Claudio Casali da Rocha100 enrolled1 locationNCT07167329